The process begins with the collection of T cells from the patient's blood. These T cells are then genetically modified in the laboratory to express specific receptors that can recognize cancer-specific antigens. Once these engineered T cells are infused back into the patient, they are able to target and destroy cancer cells. This approach is particularly promising for treating cancers that have been resistant to conventional therapies.
